Hanall Biopharma Croissance future

Future contrôle des critères 4/6

Hanall Biopharma devrait augmenter ses bénéfices et son chiffre d'affaires de 61.1% et de 13.4% par an respectivement. Le BPA devrait croître de de 98.3% par an. Le rendement des capitaux propres devrait être 12.1% dans 3 ans.

Informations clés

61.1%

Taux de croissance des bénéfices

98.3%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	31.4%
Taux de croissance des recettes	13.4%
Rendement futur des capitaux propres	12.1%
Couverture par les analystes	Good
Dernière mise à jour	25 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Oct 14

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Jun 26

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

May 22

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Mar 13

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Feb 12

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Jan 25

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Jan 04

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Dec 14

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Nov 21

Prévisions de croissance des bénéfices et des revenus

KOSE:A009420 - Estimations futures des analystes et données financières antérieures (KRW Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	190,417	58,575	44,133	46,000	6
12/31/2025	165,733	22,880	24,400	27,233	6
12/31/2024	140,750	-3,000	7,300	9,300	2
9/30/2024	134,245	-6,288	-10,130	8,834	N/A
6/30/2024	130,374	-6,191	7,368	23,537	N/A
3/31/2024	140,199	4,439	11,622	22,456	N/A
12/31/2023	134,910	3,509	20,445	29,643	N/A
9/30/2023	133,308	6,049	20,476	29,993	N/A
6/30/2023	129,981	6,464	2,734	10,524	N/A
3/31/2023	114,812	-919	10,130	18,084	N/A
12/31/2022	109,995	251	17,587	25,264	N/A
9/30/2022	104,764	-376	10,636	20,123	N/A
6/30/2022	100,596	949	10,515	20,067	N/A
3/31/2022	97,783	4,288	1,719	12,083	N/A
12/31/2021	101,594	8,896	-8,162	840	N/A
9/30/2021	98,500	16,123	72	6,659	N/A
6/30/2021	95,140	17,778	-4,183	1,719	N/A
3/31/2021	94,304	20,413	-5,913	1,778	N/A
12/31/2020	88,602	19,765	-6,460	929	N/A
9/30/2020	92,953	19,714	-20,156	-7,468	N/A
6/30/2020	98,834	21,457	1,452	14,085	N/A
3/31/2020	106,049	19,753	13,739	22,030	N/A
12/31/2019	108,452	19,174	12,215	20,491	N/A
9/30/2019	105,550	10,279	22,576	24,374	N/A
6/30/2019	101,531	7,373	10,174	11,694	N/A
3/31/2019	94,252	5,882	3,130	5,117	N/A
12/31/2018	91,839	3,300	-4,913	-2,994	N/A
9/30/2018	88,551	9,000	26,226	28,359	N/A
6/30/2018	89,131	9,149	N/A	28,894	N/A
3/31/2018	87,204	6,945	N/A	33,291	N/A
12/31/2017	84,231	5,813	N/A	42,139	N/A
9/30/2017	85,417	3,586	N/A	7,912	N/A
6/30/2017	81,809	562	N/A	-325	N/A
3/31/2017	81,807	1,355	N/A	2,825	N/A
12/31/2016	82,882	2,026	N/A	3,950	N/A
9/30/2016	82,223	-3,478	N/A	6,046	N/A
6/30/2016	79,584	-5,817	N/A	6,546	N/A
3/31/2016	79,447	-7,142	N/A	2,205	N/A
12/31/2015	80,023	-7,077	N/A	-454	N/A
9/30/2015	79,818	-16,050	N/A	1,128	N/A
6/30/2015	81,892	-13,143	N/A	280	N/A
3/31/2015	81,657	-12,865	N/A	-1,115	N/A
12/31/2014	80,880	-12,658	N/A	-3,518	N/A
9/30/2014	78,763	-11,694	N/A	-6,993	N/A
6/30/2014	77,511	-17,134	N/A	-5,677	N/A
3/31/2014	76,276	-18,966	N/A	-8,556	N/A
12/31/2013	74,228	-21,499	N/A	-7,780	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: A009420 devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 2.7% ).

Bénéfices vs marché: A009420 devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: A009420 devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de A009420 ( 13.4% par an) devrait croître plus rapidement que le marché KR ( 9.1% par an).

Croissance élevée des revenus: Le chiffre d'affaires de A009420 ( 13.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de A009420 devrait être faible dans 3 ans ( 12.1 %).

Hanall Biopharma Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates increase by 23%, revenue downgraded

Consensus EPS estimates fall by 45%, revenue upgraded

Consensus EPS estimates fall by 12%

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

Recent updates

Hanall Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of A First-In-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

Now 23% undervalued

Hanall Biopharma Co., Ltd.'s (KRX:009420) 30% Share Price Surge Not Quite Adding Up

Consensus EPS estimates increase by 23%, revenue downgraded

Now 22% undervalued after recent price drop

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Hanall Biopharma Co., Ltd. Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Hanall Biopharma Co., Ltd. (KRX:009420)

Consensus EPS estimates fall by 45%, revenue upgraded

Getting In Cheap On Hanall Biopharma Co., Ltd. (KRX:009420) Is Unlikely

Consensus EPS estimates fall by 12%

There May Be Underlying Issues With The Quality Of Hanall Biopharma's (KRX:009420) Earnings

Hanall Biopharma Co., Ltd., Annual General Meeting, Mar 28, 2024

Full year 2023 earnings released: EPS: ₩69.00 (vs ₩5.00 in FY 2022)

Price target increased by 11% to ₩44,667

Price target increased by 8.5% to ₩42,333

Consensus EPS estimates increase by 16%

New major risk - Share price stability

Price target increased by 14% to ₩35,800

Now 20% undervalued

Full year 2022 earnings released: EPS: ₩5.00 (vs ₩174 in FY 2021)

Less than half of directors are independent

Hanall's Second FcRn Inhibitor HL161ANS to Be Added to the Development Program of Its Licensed Partner

Price target decreased to ₩29,000

Less than half of directors are independent

Price target decreased to ₩45,500

First quarter 2021 earnings released: EPS ₩88.00 (vs ₩76.00 in 1Q 2020)

Hanall Biopharma Co.,Ltd, Annual General Meeting, Mar 26, 2021

Full year 2020 earnings released: EPS ₩386 (vs ₩375 in FY 2019)

New 90-day low: ₩23,400

Introducing Hanall BiopharmaLtd (KRX:009420), The Stock That Zoomed 103% In The Last Five Years

Investor sentiment deteriorated over the past week

New 90-day low: ₩32,050

What Kind Of Investors Own Most Of Hanall Biopharma Co.,Ltd (KRX:009420)?

Hanall Biopharma Co.,Ltd's (KRX:009420) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: ₩39,000

Hanall BiopharmaLtd (KRX:009420) Is Growing Earnings But Are They A Good Guide?

Here's Why We Think Hanall BiopharmaLtd (KRX:009420) Is Well Worth Watching

Market bids up stock over the past week

New 90-day low: ₩27,600

Price target raised to ₩41,500

New 90-day high - ₩34,600

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance